Federated Hermes’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$396K Buy
4,945
+800
+19% +$66K ﹤0.01% 1359
2025
Q4
$353K Sell
4,145
-85
-2% -$6.98K ﹤0.01% 1396
2025
Q3
$329K Buy
4,230
+1,677
+66% +$131K ﹤0.01% 1422
2025
Q2
$200K Sell
2,553
-39
-2% -$2.91K ﹤0.01% 1497
2025
Q1
$188K Buy
2,592
+1,456
+128% +$104K ﹤0.01% 1498
2024
Q4
$84.1K Sell
1,136
-2,068
-65% -$145K ﹤0.01% 1589
2024
Q3
$211K Buy
3,204
+1,580
+97% +$115K ﹤0.01% 1471
2024
Q2
$150K Sell
1,624
-201
-11% -$17.8K ﹤0.01% 1519
2024
Q1
$174K Sell
1,825
-178
-9% -$15K ﹤0.01% 1519
2023
Q4
$153K Sell
2,003
-10,491
-84% -$730K ﹤0.01% 1546
2023
Q3
$866K Sell
12,494
-6,879
-36% -$553K ﹤0.01% 1161
2023
Q2
$1.83M Buy
19,373
+6,485
+50% +$564K ﹤0.01% 987
2023
Q1
$1.07M Buy
12,888
+9,016
+233% +$709K ﹤0.01% 1153
2022
Q4
$289K Sell
3,872
-740,680
-99% -$57.1M ﹤0.01% 1495
2022
Q3
$61.5M Buy
744,552
+1,041
+0.1% +$100K 0.18% 141
2022
Q2
$70.7M Sell
743,511
-56,616
-7% -$5.86M 0.19% 138
2022
Q1
$94.2M Sell
800,127
-24,807
-3% -$2.78M 0.21% 129
2021
Q4
$107M Buy
824,934
+866
+0.1% +$101K 0.2% 140
2021
Q3
$93.3M Buy
824,068
+1,623
+0.2% +$185K 0.18% 160
2021
Q2
$85.2M Buy
822,445
+439
+0.1% +$41.4K 0.16% 178
2021
Q1
$68.8M Sell
822,006
-249
-0% -$21.1K 0.13% 202
2020
Q4
$75M Sell
822,255
-403
-0% -$33.4K 0.15% 172
2020
Q3
$65.7M Sell
822,658
-12,012
-1% -$937K 0.15% 158
2020
Q2
$57.7M Sell
834,670
-16,433
-2% -$1.17M 0.14% 165
2020
Q1
$53.5M Sell
851,103
-33,474
-4% -$2.41M 0.16% 149
2019
Q4
$68.8M Buy
884,577
+15,615
+2% +$1.22M 0.15% 157
2019
Q3
$63.7M Sell
868,962
-78,276
-8% -$5.5M 0.16% 152
2019
Q2
$58.3M Sell
947,238
-90,303
-9% -$5.46M 0.14% 161
2019
Q1
$66.2M Sell
1,037,541
-30,615
-3% -$1.75M 0.16% 133
2018
Q4
$54.5M Sell
1,068,156
-937,917
-47% -$47.5M 0.15% 145
2018
Q3
$116M Sell
2,006,073
-116,661
-5% -$5.71M 0.27% 74
2018
Q2
$103M Sell
2,122,734
-302,601
-12% -$14.1M 0.3% 78
2018
Q1
$113M Sell
2,425,335
-95,976
-4% -$4.17M 0.33% 64
2017
Q4
$94.7M Sell
2,521,311
-1,545
-0.1% -$56.7K 0.27% 74
2017
Q3
$91.9M Buy
2,522,856
+191,763
+8% +$7.31M 0.26% 75
2017
Q2
$91.9M Sell
2,331,093
-17,055
-0.7% -$623K 0.26% 67
2017
Q1
$73.6M Buy
2,348,148
+477,114
+26% +$14.9M 0.21% 87
2016
Q4
$58.4M Buy
1,871,034
+891,966
+91% +$28.9M 0.18% 113
2016
Q3
$39.3M Sell
979,068
-124,233
-11% -$4.68M 0.11% 142
2016
Q2
$36.7M Buy
1,103,301
+962,562
+684% +$32.9M 0.11% 151
2016
Q1
$4.14M Buy
140,739
+131,976
+1,506% +$3.64M 0.01% 597
2015
Q4
$230K Sell
8,763
-368,799
-98% -$9.58M ﹤0.01% 1455
2015
Q3
$8.95M Buy
377,562
+237,792
+170% +$5.74M 0.03% 456
2015
Q2
$3.32M Sell
139,770
-150,504
-52% -$3.4M 0.01% 742
2015
Q1
$6.89M Buy
290,274
+36,672
+14% +$823K 0.02% 530
2014
Q4
$5.38M Buy
253,602
+204,330
+415% +$4.1M 0.02% 588
2014
Q3
$839K Buy
49,272
+6,960
+16% +$110K ﹤0.01% 1238
2014
Q2
$605K Buy
42,312
+21,984
+108% +$298K ﹤0.01% 1308
2014
Q1
$251K Buy
20,328
+2,568
+14% +$29.6K ﹤0.01% 1469
2013
Q4
$195K Buy
17,760
+6,954
+64% +$78.4K ﹤0.01% 1487
2013
Q3
$125K Buy
10,806
+9,000
+498% +$105K ﹤0.01% 1529
2013
Q2
$20K Buy
+1,806
New +$21.4K ﹤0.01% 1652

Other funds holding EW

Federated Hermes's EW Position: Q1 2026 in Review

Federated Hermes increased its Edwards Lifesciences (EW) stake by 19% in Q1 2026, buying an estimated $66K and bringing the position to 4,945 shares worth $396K. The position accounts for ﹤0.01% of the portfolio, ranked #1359.

Federated Hermes first reported a position in EW in Q2 2013 and has held it in 52 quarters since. The position peaked at $116M in Q3 2018. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Federated Hermes held 4,945 shares of Edwards Lifesciences worth $396K as of Q1 2026.
  • Federated Hermes bought 800 Edwards Lifesciences shares in Q1 2026, an estimated $66K.
  • Edwards Lifesciences made up ﹤0.01% of Federated Hermes's portfolio in Q1 2026, its #1359 holding.
  • Federated Hermes first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 52 quarters since.
  • Federated Hermes's Edwards Lifesciences position peaked at $116M in Q3 2018.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Federated Hermes's 13F filing for Q1 2026, filed 11 May 2026.